Semler Scientific (NASDAQ:SMLR) Shares Down 6.1% – Should You Sell?

Semler Scientific, Inc. (NASDAQ:SMLR)’s share price fell 6.1% on Tuesday . The company traded as low as $54.74 and last traded at $55.36. 133,518 shares were traded during mid-day trading, a decline of 63% from the average session volume of 359,435 shares. The stock had previously closed at $58.94.

Semler Scientific Stock Performance

The stock’s fifty day moving average price is $55.45 and its 200-day moving average price is $38.08. The firm has a market cap of $523.12 million, a PE ratio of 27.54 and a beta of 1.18.

Semler Scientific (NASDAQ:SMLR) last released its quarterly earnings data on Monday, November 4th. The company reported $0.72 EPS for the quarter, topping the consensus estimate of $0.37 by $0.35. Semler Scientific had a net margin of 27.00% and a return on equity of 20.31%. The business had revenue of $13.51 million for the quarter.

Institutional Trading of Semler Scientific

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SMLR. Newbridge Financial Services Group Inc. acquired a new position in Semler Scientific during the 2nd quarter worth $34,000. Quest Partners LLC acquired a new stake in shares of Semler Scientific in the second quarter valued at approximately $59,000. Meeder Asset Management Inc. bought a new position in shares of Semler Scientific in the second quarter worth $67,000. US Bancorp DE raised its stake in shares of Semler Scientific by 60.8% during the third quarter. US Bancorp DE now owns 3,064 shares of the company’s stock valued at $72,000 after purchasing an additional 1,158 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in Semler Scientific during the third quarter worth approximately $104,000. Hedge funds and other institutional investors own 49.37% of the company’s stock.

About Semler Scientific

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition.